Baillie Gifford & Co’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-49
Closed -$7.38K 268
2025
Q1
$7.38K Sell
49
-75,362
-100% -$12.6M ﹤0.01% 261
2024
Q4
$13.9M Buy
75,411
+6,826
+10% +$1.31M 0.01% 198
2024
Q3
$13.5M Buy
68,585
+1,048
+2% +$218K 0.01% 200
2024
Q2
$14M Buy
67,537
+3
+0% +$680 0.01% 197
2024
Q1
$18.3M Sell
67,534
-2,668
-4% -$637K 0.01% 193
2023
Q4
$16.6M Sell
70,202
-9,370
-12% -$1.84M 0.01% 202
2023
Q3
$15.6M Sell
79,572
-5,524
-6% -$1.13M 0.01% 196
2023
Q2
$17.9M Sell
85,096
-394
-0.5% -$78.4K 0.02% 185
2023
Q1
$17.3M Buy
85,490
+14,118
+20% +$3.2M 0.02% 191
2022
Q4
$15.6M Sell
71,372
-527
-0.7% -$115K 0.02% 196
2022
Q3
$14.2M Buy
71,899
+56,103
+355% +$12.1M 0.01% 201
2022
Q2
$3.38M Buy
+15,796
New +$3.86M ﹤0.01% 256

Other funds holding CRL